At the news
? NEUTRALIMPACT 5/10 8-K filed Apr 15, 2026 at 08:05 ET
Reviva Pharmaceuticals announced a $10 million financing completed on March 20, 2026, boosting its cash position to approximately $23 million (unaudited), which it expects will fund operations into Q1 2027. The company also detailed plans to extend the patent life of its lead drug candidate, brilaroxazine, potentially through 2046, by filing a new composition of matter patent and seeking FDA alignment to use this new form in its upcoming Phase 3 trial (RECOVER-2), which is expected to begin patient enrollment in Q3 2026.
- Completed a $10 million financing on March 20, 2026.
- Reports approximately $23 million in cash and cash equivalents (unaudited) post-financing, funding operations into Q1 2027.
- Filed a new composition of matter patent application for brilaroxazine to extend commercial exclusivity, potentially through 2046.
- Plans to seek FDA alignment to switch to the new form of brilaroxazine in the RECOVER-2 Phase 3 trial, with feedback expected mid-year 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access